Cardiovascular disease: A factor XIIa inhibitory antibody provides thromboprotection in extracorporeal circulation without increasing bleeding risk

Science Translational Medicine

Volumn 6, Issue 222, 2014, Pages

  Larsson, Magnus ^a,b   Rayzman, Veronika ^c   Nolte, Marc W ^d   Nickel, Katrin F ^a,b,e   Björkqvist, Jenny ^a,b   Jämsä, Anne ^a,b   Hardy, Matthew P ^c   Fries, Marion ^d   Schmidbauer, Stefan ^d   Hedenqvist, Patricia ^f   Broomé, Michael ^a,b   Pragst, Ingo ^d   Dickneite, Gerhard ^d   Wilson, Michael J ^c   Nash, Andrew D ^c   Panousis, Con ^c   Renné, Thomas ^a,b,e  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c CSL LIMITED   (Australia)

^d CSL BEHRING GMBH   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 12A; HEPARIN;

ANIMAL; ARTERIOVENOUS SHUNT; ARTICLE; BLEEDING; BLOOD CLOTTING; DISEASE MODEL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVE SITE; EPITOPE MAPPING; EXTRACORPOREAL CIRCULATION; HUMAN; METABOLISM; MOUSE; RABBIT; RISK FACTOR; SPECIES DIFFERENCE; THROMBOSIS;

ANIMALS; ANTIBODIES; ARTERIOVENOUS SHUNT, SURGICAL; BLOOD COAGULATION; CATALYTIC DOMAIN; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPITOPE MAPPING; EXTRACORPOREAL CIRCULATION; FACTOR XIIA; HEMORRHAGE; HEPARIN; HUMANS; MICE; RABBITS; RISK FACTORS; SPECIES SPECIFICITY; THROMBOSIS;

EID: 84893834884     PISSN: 19466234     EISSN: 19466242     Source Type: Journal    
DOI: 10.1126/scitranslmed.3006804     Document Type: Article

References (65)

1. N. Mackman, Triggers, targets and treatments for thrombosis. Nature 451, 914-918 (2008).
2. J. W. Eikelboom, J. I. Weitz, New anticoagulants. Circulation 121, 1523-1532 (2010).
3. L. M. Leeb-Lundberg, F. Marceau, W. Müller-Esterl, D. J. Pettibone, B. L. Zuraw, International union of pharmacology. XLV. Classification of the kinin receptor family: From molecular mechanisms to pathophysiological consequences. Pharmacol. Rev. 57, 27-77 (2005).
4. T. Renné, A. H. Schmaier, K. F. Nickel, M. Blombäck, C. Maas, In vivo roles of factor XII. Blood 120, 4296-4303 (2012).
5. N. Mackman, Role of tissue factor in hemostasis, thrombosis, and vascular development. Arterioscler. Thromb. Vasc. Biol. 24, 1015-1022 (2004).
6. T. Renné, M. Pozgajová, S. Grüner, K. Schuh, H. U. Pauer, P. Burfeind, D. Gailani, B. Nieswandt, Defective thrombus formation in mice lacking coagulation factor XII. J. Exp. Med. 202, 271-281 (2005).
7. C. Kleinschnitz, G. Stoll, M. Bendszus, K. Schuh, H. U. Pauer, P. Burfeind, C. Renné, D. Gailani, B. Nieswandt, T. Renné, Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J. Exp. Med. 203, 513-518 (2006).
8. F. Müller, N. J. Mutch, W. A. Schenk, S. A. Smith, L. Esterl, H. M. Spronk, S. Schmidbauer, W. A. Gahl, J. H. Morrissey, T. Renné, Platelet polyphosphates are proinflammatory and procoagulant mediators in vivo. Cell 139, 1143-1156 (2009).
9. R. M. Sniecinski, W. L. Chandler, Activation of the hemostatic system during cardiopulmonary bypass. Anesth. Analg. 113, 1319-1333 (2011).
10. J. Sanchez, G. Elgue, J. Riesenfeld, P. Olsson, Studies of adsorption, activation, and inhibition of factor XII on immobilized heparin. Thromb. Res. 89, 41-50 (1998).
11. V. P. Addonizio, C. A. Fisher, J. C. Bowen, G. C. Palatianos, R. W. Colman, L. H. Edmunds Jr., Prostacyclin in lieu of anticoagulation with heparin for extracorporeal circulation. Trans. Am. Soc. Artif. Intern. Organs 27, 304-307 (1981).
12. G. Fuhrer, M. J. Gallimore, W. Heller, H. E. Hoffmeister, Aprotinin in cardiopulmonary bypass-Effects on the Hageman factor (FXII)-kallikrein system and blood loss. Blood Coagul. Fibrinolysis 3, 99-104 (1992).
13. Y. T. Wachtfogel, C. E. Hack, J. H. Nuijens, C. Kettner, T. M. Reilly, R. M. Knabb, R. Bischoff, H. Tschesche, H. Wenzel, U. Kucich, Selective kallikrein inhibitors alter human neutrophil elastase release during extracorporeal circulation. Am. J. Physiol. 268, H1352-H1357 (1995).
14. Y. T. Wachtfogel, R. Bischoff, R. Bauer, C. E. Hack, J. H. Nuijens, U. Kucich, S. Niewiarowski, L. H. Edmunds Jr., R. W. Colman, Alpha 1-antitrypsin Pittsburgh (Met358®Arg) inhibits the contact pathway of intrinsic coagulation and alters the release of human neutrophil elastase during simulated extracorporeal circulation. Thromb. Haemost. 72, 843-847 (1994).
15. N. Gikakis, M. M. Khan, Y. Hiramatsu, J. H. Gorman III, C. E. Hack, L. Sun, A. K. Rao, S. Niewiarowski, R. W. Colman, L. H. Edmunds Jr., Effect of factor Xa inhibitors on thrombin formation and complement and neutrophil activation during in vitro extracorporeal circulation. Circulation 94, 341-346 (1996).
16. G. Annich, T. White, D. Damm, Y. Zhao, F. Mahdi, J. Meinhardt, S. Rebello, B. Lucchesi, R. H. Bartlett, A. H. Schmaier, Recombinant Kunitz protease inhibitory domain of the amyloid beta-protein precursor as an anticoagulant in venovenous extracorporeal circulation in rabbits. Thromb. Haemost. 82, 1474-1481 (1999).
17. G. M. Annich, J. P. Meinhardt, K. A. Mowery, B. A. Ashton, S. I. Merz, R. B. Hirschl, M. E. Meyerhoff, R. H. Bartlett, Reduced platelet activation and thrombosis in extracorporeal circuits coated with nitric oxide release polymers. Crit. Care Med. 28, 915-920 (2000).
18. E. D. Rauch, A. H. Stammers, B. L. Mejak, S. N. Vang, T. W. Viessman, The effects of nitric oxide on coagulation during simulated extracorporeal membrane oxygenation. J. Extra Corpor. Tech. 32, 214-219 (2000).
19. A. M. Skrzypchak, N. G. Lafayette, R. H. Bartlett, Z. Zhou, M.C. Frost, M. E. Meyerhoff, M. M. Reynolds, G. M. Annich, Effect of varying nitric oxide release to prevent platelet consumption and preserve platelet function in an in vivo model of extracorporeal circulation. Perfusion 22, 193-200 (2007).
20. S. A. Conrad, P. T. Rycus, H. Dalton, Extracorporeal Life Support Registry Report 2004. ASAIO J. 51, 4-10 (2005).
21. I. Hagedorn, S. Schmidbauer, I. Pleines, C. Kleinschnitz, U. Kronthaler, G. Stoll, G. Dickneite, B. Nieswandt, Factor XIIa inhibitor recombinant human albumin Infestin-4 abolishes occlusive arterial thrombus formation without affecting bleeding. Circulation 121, 1510-1517 (2010).
22. 1-esterase inhibitor. Thromb. Haemost. 83, 874-881 (2000).
23. H. U. Pauer, T. Renné, B. Hemmerlein, T. Legler, S. Fritzlar, I. Adham, W. Müller-Esterl, G. Emons, U. Sancken, W. Engel, P. Burfeind, Targeted deletion of murine coagulation factor XII gene-A model for contact phase activation in vivo. Thromb. Haemost. 92, 503-508 (2004).
24. B. Ghebrehiwet, M. Silverberg, A. P. Kaplan, Activation of the classical pathway of complement by Hageman factor fragment. J. Exp. Med. 153, 665-676 (1981).
25. A. Majeed, S. Schulman, Bleeding and antidotes in new oral anticoagulants. Best Pract. Res. Clin. Haematol. 26, 191-202 (2013).
26. S. Schulman, R. J. Beyth, C. Kearon, M. N. Levine; American College of Chest Physicians, Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133, 257S-298S (2008).
27. R. D. Mayforth, J. Quintáns, Designer and catalytic antibodies. N. Engl. J. Med. 323, 173-178 (1990).
28. Y. Decrem, G. Rath, V. Blasioli, P. Cauchie, S. Robert, J. Beaufays, J. M. Frère, O. Feron, J. M. Dogné, C. Dessy, L. Vanhamme, E. Godfroid, Ir-CPI, a coagulation contact phase inhibitor from the tick Ixodes ricinus, inhibits thrombus formation without impairing hemostasis. J. Exp. Med. 206, 2381-2395 (2009).
29. H. Saito, T. Ishihara, H. Suzuki, T. Watanabe, Production and characterization of a murine monoclonal antibody against a heavy chain of Hageman factor (factor XII). Blood 65, 1263-1268 (1985).
30. E. J. Small, J. A. Katzmann, R. P. Tracy, O. D. Ratnoff, G. H. Goldsmith Jr., B. Everson, A monoclonal antibody that inhibits activation of human Hageman factor (factor XII). Blood 65, 202-210 (1985).
31. R. A. Pixley, L. G. Stumpo, K. Birkmeyer, L. Silver, R. W. Colman, A monoclonal antibody recognizing an icosapeptide sequence in the heavy chain of human factor XII inhibits surface-catalyzed activation. J. Biol. Chem. 262, 10140-10145 (1987).
32. G. A. LaRusch, F. Mahdi, Z. Shariat-Madar, G. Adams, R. G. Sitrin, W. M. Zhang, K. R. McCrae, A. H. Schmaier, Factor XII stimulates ERK1/2 and Akt through uPAR, integrins, and the EGFR to initiate angiogenesis. Blood 115, 5111-5120 (2010).
33. R. A. Pixley, R. De La Cadena, J. D. Page, N. Kauffman, E. G. Wyshock, A. Chang, F. B. Taylor Jr., R. W. Colman, The contact system contributes to hypotension but not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a monoclonal anti-factor XII antibody to block contact activation in baboons. J. Clin. Invest. 91, 61-68 (1993).
34. R. Pawlinski, J. G. Wang, A. P. Owens III, J. Williams, S. Antoniak, M. Tencati, T. Luther, J. W. Rowley, E. N. Low, A. S. Weyrich, N. Mackman, Hematopoietic and nonhematopoietic cell tissue factor activates the coagulation cascade in endotoxemic mice. Blood 116, 806-814 (2010).
35. A. S. Revenko, D. Gao, J. R. Crosby, G. Bhattacharjee, C. Zhao, C. May, D. Gailani, B. P. Monia, A. R. MacLeod, Selective depletion of plasma prekallikrein or coagulation factor XII inhibits thrombosis in mice without increased risk of bleeding. Blood 118, 5302-5311 (2011).
36. C. Kuhli, I. Scharrer, F. Koch, C. Ohrloff, L. O. Hattenbach, Factor XII deficiency: A thrombophilic risk factor for retinal vein occlusion. Am. J. Ophthalmol. 137, 459-464 (2004).
37. L. T. Goodnough, H. Saito, O. D. Ratnoff, Thrombosis or myocardial infarction in congenital clotting factor abnormalities and chronic thrombocytopenias: A report of 21 patients and a review of 50 previously reported cases. Medicine 62, 248-255 (1983).
38. A. Girolami, M. L. Randi, S. Gavasso, A. M. Lombardi, F. Spiezia, The occasional venous thromboses seen in patients with severe (homozygous) FXII deficiency are probably due to associated risk factors: A study of prevalence in 21 patients and review of the literature. J. Thromb. Thrombolysis 17, 139-143 (2004).
39. S. Zeerleder, M. Schloesser, M. Redondo, W. A. Wuillemin, W. Engel, M. Furlan, B. Lämmle, Reevaluation of the incidence of thromboembolic complications in congenital factor XII deficiency-A study on 73 subjects from 14 Swiss families. Thromb. Haemost. 82, 1240-1246 (1999).
40. T. Koster, F. R. Rosendaal, E. Briët, J. P. Vandenbroucke, John Hageman's factor and deep-vein thrombosis: Leiden Thrombophilia Study. Br. J. Haematol. 87, 422-424 (1994).
41. O. Salomon, D. M. Steinberg, N. Koren-Morag, D. Tanne, U. Seligsohn, Reduced incidence of ischemic stroke in patients with severe factor XI deficiency. Blood 111, 4113-4117 (2008).
42. O. Salomon, D. M. Steinberg, M. Zucker, D. Varon, A. Zivelin, U. Seligsohn, Patients with severe factor XI deficiency have a reduced incidence of deep-vein thrombosis. Thromb. Haemost. 105, 269-273 (2011).
43. J. R. Crosby, U. Marzec, A. S. Revenko, C. Zhao, D. Gao, A. Matafonov, D. Gailani, A. R. MacLeod, E. I. Tucker, A. Gruber, S. R. Hanson, B. P. Monia, Antithrombotic effect of antisense factor XI oligonucleotide treatment in primates. Arterioscler. Thromb. Vasc. Biol. 33, 1670-1678 (2013).
44. A. Gruber, S. R. Hanson, Factor XI-dependence of surface-and tissue factor-initiated thrombus propagation in primates. Blood 102, 953-955 (2003).
45. E. I. Tucker, U. M. Marzec, T. C. White, S. Hurst, S. Rugonyi, O. J. McCarty, D. Gailani, A. Gruber, S. R. Hanson, Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI. Blood 113, 936-944 (2009).
46. Q. Cheng, E. I. Tucker, M. S. Pine, I. Sisler, A. Matafonov, M. F. Sun, T. C. White-Adams, S. A. Smith, S. R. Hanson, O. J. McCarty, T. Renné, A. Gruber, D. Gailani, A role for factor XIIa-mediated factor XI activation in thrombus formation in vivo. Blood 116, 3981-3989 (2010).
47. M. Takahashi, A. Yamashita, S. Moriguchi-Goto, C. Sugita, T. Matsumoto, S. Matsuda, Y. Sato, T. Kitazawa, K. Hattori, M. Shima, Y. Asada, Inhibition of factor XI reduces thrombus formation in rabbit jugular vein under endothelial denudation and/or blood stasis. Thromb. Res. 125, 464-470 (2010).
48. A. Yamashita, K. Nishihira, T. Kitazawa, K. Yoshihashi, T. Soeda, K. Esaki, T. Imamura, K. Hattori, Y. Asada, Factor XI contributes to thrombus propagation on injured neointima of the rabbit iliac artery. J. Thromb. Haemost. 4, 1496-1501 (2006).
49. V. Baeriswyl, S. Calzavarini, C. Gerschheimer, P. Diderich, A. Angelillo-Scherrer, C. Heinis, Development of a selective peptide macrocycle inhibitor of coagulation factor XII toward the generation of a safe antithrombotic therapy. J. Med. Chem. 56, 3742-3746 (2013).
50. R. de Vroege, R. Huybregts, W. van Oeveren, J. van Klarenbosch, G. Linley, J. Mutlu, E. Jansen, E. Hack, L. Eijsman, C. Wildevuur, The impact of heparin-coated circuits on hemodynamics during and after cardiopulmonary bypass. Artif. Organs 29, 490-497 (2005).
51. H. P. Wendel, A. M. Scheule, F. S. Eckstein, G. Ziemer, Haemocompatibility of paediatric membrane oxygenators with heparin-coated surfaces. Perfusion 14, 21-28 (1999).
52. M. Pieri, O. G. Turla, M. G. Calabrò, L. Ruggeri, N. Agracheva, A. Zangrillo, F. Pappalardo, A new phosphorylcholine-coated polymethylpentene oxygenator for extracorporeal membrane oxygenation: A preliminary experience. Perfusion 28, 132-137 (2013).
53. C. G. Cornelissen, M. Dietrich, K. Gromann, J. Frese, S. Krueger, J. S. Sachweh, S. Jockenhoevel, Fibronectin coating of oxygenator membranes enhances endothelial cell attachment. Biomed. Eng. Online 12, 7 (2013).
54. L. Irvine, S. Sundaram, J. M. Courtney, D. P. Taggart, D. J. Wheatley, G. D. Lowe, Monitoring of factor XII activity and granulocyte elastase release during cardiopulmonary bypass. ASAIO Trans. 37, 569-571 (1991).
55. A. K. Mangal, S. C. Naiman, Hageman factor deficiency and oral contraceptives. Lancet 1, 774 (1980).
56. O. D. Ratnoff, The demise of John Hageman. N. Engl. J. Med. 279, 760-761 (1968).
57. N. J. Mutch, R. Engel, S. Uitte de Willige, H. Philippou, R. A. Ariëns, Polyphosphate modifies the fibrin network and down-regulates fibrinolysis by attenuating binding of tPA and plasminogen to fibrin. Blood 115, 3980-3988 (2010).
58. J. Konings, J. W. Govers-Riemslag, H. Philippou, N. J. Mutch, J. I. Borissoff, P. Allan, S. Mohan, G. Tans, H. Ten Cate, R. A. Ariëns, Factor XIIa regulates the structure of the fibrin clot independently of thrombin generation through direct interaction with fibrin. Blood 118, 3942-3951 (2011).
59. T. Jostock, M. Vanhove, E. Brepoels, R. Van Gool, M. Daukandt, A. Wehnert, R. Van Hegelsom, D. Dransfield, D. Sexton, M. Devlin, A. Ley, H. Hoogenboom, J. Müllberg, Rapid generation of functional human IgG antibodies derived from Fab-on-phage display libraries. J. Immunol. Methods 289, 65-80 (2004).
60. P. Hedenqvist, A. Edner, Å. Fahlman, M. Jensen-Waern, Continuous intravenous anaesthesia with sufentanil and midazolam in medetomidine premedicated New Zealand White rabbits. BMC Vet. Res. 9, 21 (2013).
61. C. Oschatz, C. Maas, B. Lecher, T. Jansen, J. Björkqvist, T. Tradler, R. Sedlmeier, P. Burfeind, S. Cichon, S. Hammerschmidt, W. Müller-Esterl, W. A. Wuillemin, G. Nilsson, T. Renné, Mast cells increase vascular permeability by heparin-initiated bradykinin formation in vivo. Immunity 34, 258-268 (2011).
62. T. Renné, J. Dedio, J. C. Meijers, D. Chung, W. Müller-Esterl, Mapping of the discontinuous H-kininogen binding site of plasma prekallikrein. Evidence for a critical role of apple domain-2. J. Biol. Chem. 274, 25777-25784 (1999).
63. T. Renné, J. Dedio, G. David, W. Müller-Esterl, High molecular weight kininogen utilizes heparan sulfate proteoglycans for accumulation on endothelial cells. J. Biol. Chem. 275, 33688-33696 (2000).
64. Y. Wang, M. Li, S. Stadler, S. Correll, P. Li, D. Wang, R. Hayama, L. Leonelli, H. Han, S. A. Grigoryev, C. D. Allis, S. A. Coonrod, Histone hypercitrullination mediates chromatin decondensation and neutrophil extracellular trap formation. J. Cell Biol. 184, 205-213 (2009).
65. E. R. Weibel, Stereological Methods: Practical Methods for Biological Morphometry (Academic Press, London, 1979), vol. 1.